



Quarterly Report

Third Quarter 2006

Antimicrobial Resistance Surveillance in Human Medicine

Consortium

Interaction in Health / Public Health Consultants
IDA Solutions
Trnava University

Date: 10 October 2006

Reference: MAT05/HR/9/2

Table of Contents

| | |
|---|-------------------------------------|
| <i>Table of Contents</i> | 2 |
| <i>Acronyms</i> | 3 |
| 1 Introduction | 4 |
| 1.1 Terms of Reference and Consortium | 4 |
| 1.2 Summary of the quarterly report | 4 |
| 2 Progress in the reporting phase | 5 |
| 2.1 Progress Report | 5 |
| 2.1.1 PAC and programme management | Error! Bookmark not defined. |
| 2.1.2 The study visit..... | Error! Bookmark not defined. |
| 2.1.3 Expected Result 1: Intersectoral Coordination Mechanism | 5 |
| 2.1.4 Expected Result 2: Surveillance System..... | 6 |
| 2.1.5 Expected Result 3: Guideline formulation..... | 7 |
| 2.2 Human Resource Utilisation | 8 |
| 2.2.1 Result 1 ICM..... | 8 |
| 2.2.2 Result 2 Surveillance | 8 |
| 2.2.3 Result 3 Guidelines | 8 |
| 3 Implementation issues | 9 |
| 3.1 Specific Issues | 9 |
| 3.2 ICM | 9 |
| 3.3 Surveillance | 9 |
| 3.4 Guidelines | 9 |
| 4 Plans for the next reporting period | 10 |
| 4.1 Detailed work plan | 10 |
| 4.1.1 Result 1 ICM..... | 10 |
| 4.1.2 Result 2 Surveillance | 10 |
| 4.1.3 Result 3 Guidelines | 10 |
| 4.2 Human resources allocation | 10 |
| 4.2.1 Result 1 ICM..... | 10 |
| 4.2.2 Result 2 Surveillance | 10 |
| 4.2.3 Result 3 Guidelines | 11 |
| <i>Annex 1 Logical Framework</i> | 12 |
| <i>Annex 2 Gantt Chart</i> | 17 |
| <i>Annex 3 Programme Study Visit</i> | 21 |
| <i>Annex 4 Evaluation by participants</i> | <i>Error! Bookmark not defined.</i> |

Acronyms

| | |
|------------|--|
| ABRES | Antibiotic Resistance (coordinating committee) |
| AGREE | Appraisal of Guidelines, Research and Evaluation |
| AR | Antimicrobial Resistance |
| ARC | Antimicrobial Resistance Control |
| CBO | Institute for Quality in Health Care (the Netherlands) |
| CLSI | Clinical and Laboratory Standards Institute |
| CME | Continuing Medical Education |
| DDD method | Defined Daily Dose |
| EARSS | European Antimicrobial Resistance Surveillance System |
| EU | European Union |
| EUCAST | European Committee on Antimicrobial Susceptibility Testing |
| ESCMID | European Society of Clinical Microbiology and Infectious Diseases |
| ESGAP | European Study Group on Antibiotic Policies |
| ESGNI | European Study Group on Nosocomial Infections |
| EVD | Economische Voorlichtings Dienst |
| FDA | Food and Drugs Agency |
| GPs | General Practitioners |
| ICM | Intersectoral Co-ordination Mechanism |
| ICT | Information and Communication technology |
| IDA | International Dispensary Agency |
| ISKRA | Intersectoral Society for Control of Resistance of Antimicrobials. |
| LIS | Laboratory Information System |
| MAFWM | Ministry of Agriculture, Forestry and Water Management |
| MHSW | Ministry of Health and Social Welfare |
| MPAP | Matra Pre-Accession Programme |
| MRSA | Methicillin Resistant Staphylococcus Aureus |
| NEQAS | National external Quality Assessment Services |
| NHG | Dutch Society for General Practitioners |
| RIVM | Dutch National Institute for Health and Environment |
| SIGN | Scottish Intercollegiate Guideline Network |
| SWAB | Dutch Working Party for Antimicrobial Policy |
| TB | Tuberculosis |
| TOR | Terms of Reference |
| VWS | Dutch Ministry of Health Welfare and Sport |
| WIP | Working Party on Infection Prevention |
| WHONET | World Health Organisation Network |

1 Introduction

1.1 Terms of Reference and Consortium

The project Antimicrobial Resistance Surveillance in Human Health is financed by the Netherlands Ministry of Foreign Affairs through the EVD agency MPAP programme. The project started on 1 January 2006 and will last until 31 December 2007. The project aims to contribute to the accession of Croatia to the European Union. In particular, the project aims to assist Croatia in implementing EU-directives and recommendations in the field of antimicrobial resistance and the sound use of antibiotics.

The purpose of the project is strengthening the Croatian institutional structure engaged in surveillance of antimicrobial resistance.

The following project results are anticipated to be achieved:

1. An Intersectoral Co-ordination Mechanism (ICM) in the field of antimicrobial resistance established and functional;
2. A surveillance system for antimicrobial resistance and use of antibiotics established, based on national policy that is in line with the EU strategy for antimicrobial resistance;
3. Guidelines for sound use of antibiotics in the human sector formulated and implemented.

According to the Terms of Reference, the Ministry of Health and Social Welfare (MHSW) is the counterpart of the project and the National Reference Centre for Antibiotic Resistance Surveillance of the Ministry of Health and Social Welfare is the beneficiary of the project.

A consortium consisting of Public Health Consultants/Interaction in Health, IDA Solutions and Trnava University (Slovak Republic) is providing consultancy services, in collaboration with the Dutch Working Party for Antimicrobial Policy (SWAB), the Dutch National Institute for Health and Environment (RIVM) and the Dutch Ministry of Health Welfare and Sport (VWS).

1.2 Summary of the quarterly report

Chapter 2 of this report gives an overview of activities implemented.

Also an assessment of the ICT infrastructure was made, including possibilities for electronic communication. Plans were drafted for upgrading the hardware in the reference centre and improving software for data communication.

Chapter 4 reflects the plans for the next quarter.

In the annexes of the logical framework and the Gantt Chart are reflected and information concerning the study visit.

2 Progress in the reporting phase

2.1 Progress Report

2.1.1 Expected Result 1: Intersectoral Coordination Mechanism

During this quarter, the MHSW and the National Reference Centre for Antimicrobial Resistance continued to work on a draft ordinance and draft policy and action plan for the Ministry of Health and Social Welfare. The ordinance will outline the composition and the tasks of the Intersectoral Coordination Mechanism (ISKRA). The draft policy and action plan will be presented to ISKRA after the members have been appointed. After approval by ISKRA members, it will be presented to MHSW for endorsement. This approach is a slight alteration in comparison to the plan of the project, because appointed ISKRA members will discuss the policy, rather than prospective members. This will give the proposal more authority.

During the congress on infectious diseases (23 – 26 September) the draft composition and tasks of ISKRA were presented to the participants, coming from various professional backgrounds.

| Result 1 : Intersectoral Co-ordination Mechanism (ICM) in the field of antimicrobial resistance established and functional | | | | | | |
|---|--|------------------------|----------|-----------|---|--------------------------|
| | | Expected starting date | started | Completed | In progress | Expected completion date |
| 1.1 | "zero" assess of implementation of EU recommendations on Antimicrobial Resistance Control | 14/04/06 | 14/04/06 | 05/06/06 | Small details still to be verified in MHSW | 30/04/05 |
| 1.2 | Study visit to the Netherlands | 08/05/06 | 08/05/06 | 13/05/06 | | 13/05/06 |
| 1.3 | Proposal for structure and mandate of the ICM | 01/06/06 | 05/06/06 | | 01/10/06 Draft under production | 01/07/06 |
| 1.4 | Conference on control of antimicrobial resistance, presentation of design structure and discussion | 23/09/06 | 23/09/06 | 26/09/06 | Draft structure and mandate presented. | 27/09/06 |
| 1.5 | Presentation of the proposal to the MHSW, legal instruments for backing up the ICM | 01/10/06 | | | | 31/10/06 |
| 1.6 | Outline document on policy development: topics and set-up of the document | 01/05/06 | 05/06/06 | 05/06/06 | 01/10/06 Draft under production | 31/05/06 |
| 1.7 | Round table discussions with prospective members of the ICM on policy development | 01/06/06 | | | Postponed until members are appointed by Minister | 30/06/06 |
| 1.8 | Draft policy and circulation among relevant stakeholders | 01/07/06 | | | Postponed until members are appointed by Minister | 31/07/06 |

| | | | | | | |
|------|--|----------|--|--|-------------------|----------|
| 1.9 | Presentation policy during conference | 23/09/06 | | | Outline presented | 27/09/06 |
| 1.10 | Final version of policy and presentation to MHSW | 01/10/06 | | | | 31/10/06 |
| 1.11 | Develop budgets for surveillance activities | 01/12/06 | | | | 31/12/06 |
| 1.12 | Formulate financing proposals to relevant institutions | 01/01/07 | | | | 31/01/07 |
| 1.13 | Develop growth scenarios based on available funding | 01/05/07 | | | | 31/05/07 |

2.1.2 Expected Result 2: Surveillance System

In this project the emphasis is on improvement of data communication between labs and data analysis, using software provided by WHO (WHONET).

The reference centre made an inventory of ICT in the labs involved in the surveillance programme. Ten labs use a Laboratory Information System (LIS) developed in Croatia (Justinic), which is also used for billing, procurement, etc. One lab uses WHONET, in parallel to the LIS. There are five labs, which do not use computers at all. All in all, five computers with internet connections are needed to realise data exchange. If necessary, the project could contribute to the purchase. Calipers for testing data entry in the WHONET and the LIS have been procured. If successful, in a later stage more will be procured for other labs.

A software engineer has been contracted to develop interface software for linking various versions of LIS to WHONET. Data will be analysed locally in the labs using WHONET and will be communicated to the National Reference Centre.

The procurement of a server for data storage of the national antimicrobial resistance surveillance has started.

During the congress on infectious diseases, the information strategy was not presented, as it was not the right forum to present information on this highly technical issue. Instead, a workshop was organised on MRSA control in hospitals. The aim of the workshop was to bring the surveillance to a higher level: not only data collection on prevalence of MRSA resistance, but also planning for action to reduce resistance in hospitals. In the next quarter there will be further steps in development of national guidelines and subsequent actions in this area.

| Expected result 2: Surveillance system for antimicrobial resistance and use of antibiotics established | | | | | | |
|---|--|------------------------|----------|-----------|--|--------------------------|
| | | Expected starting date | Started | Completed | In progress | Expected completion date |
| 2.1 | Inventory of automation in laboratories, information and communication | 15/04/06 | 15/05/06 | 30/06/06 | | 30/06/06 |
| 2.2 | Study visit to the Netherlands | 08/05/06 | 08/05/06 | 13/06/06 | | 13/05/06 |
| 2.3 | Plan for Improving ICT in Reference centre and labs | 01/06/06 | 06/06/06 | | Software engineer working on interface | 31/06/06 |
| 2.4 | Improving ICT in Reference centre | 01/07/06 | | | Procurement hardware started | 31/08/06 |
| 2.6 | Presentation of communication strategy during national conference | 23/09/06 | | | Not presented, instead MRSA workshop | 27/09/06 |

| | | | | | | |
|------|--|----------|--|--|--|----------|
| 2.7 | Implementing new communication system between labs | 01/10/06 | | | | 31/12/06 |
| 2.8 | Testing of new communication system labs | 01/01/07 | | | | 31/07/07 |
| 2.9 | Evaluation of new communication system | 01/10/07 | | | | 31/10/07 |
| 2.10 | Final report National Surveillance System | 01/10/07 | | | | 31/10/07 |

2.1.3 Expected Result 3: Guideline formulation

During the workshop on 23 September 7 clinical guidelines, which were produced in Croatia in the past, were analysed using the AGREE guidelines. Strengths and weaknesses of the guidelines were identified. (See annex [nn](#).) Although most of the guidelines contain useful elements, the guidelines have to be rewritten in a more systematic way, with a rigorous methodology and with the involvement of a wider range of stakeholders.

Part of the guidelines which were discussed during the workshop were produced in 2000, as part of a quality programme by MHSW. However, the programme was halted and guidelines were never introduced in practice.

It is suggested that working groups are initiated under responsibility of ISKRA, with the involvement of representatives from various professional backgrounds, e.g. clinical microbiologists, pharmacologists, General Practitioners, intensivists, and the patients and consumers association. Medical Societies can be requested to appoint people. Funding for the guideline development should be requested from the MHSW. The Matra project can contribute something and the local consultant can do some coordination work for the working groups. A facilitator is needed in the process of literature search for evidence, possibly a librarian.

During the workshop on 23 September the guidelines to start with were identified: Tonsillopharyngitis, Urinary Tract Infections, Surgical Prophylaxis, Otitis Media, and MRSA (without treatment).

| Expected result 3: Guidelines for sound use of antibiotics in the human sector formulated and implemented | | | | | | |
|--|--|------------------------|----------|-----------|-------------|--------------------------|
| | | Expected starting date | Started | Completed | In progress | Expected completion date |
| 3.1 | Study visit to the Netherlands, discuss guideline development with NHG, SWAB | 08/05/06 | 08/05/06 | 13/06/05 | | 13/05/06 |
| 3.2 | Inventory of existing clinical practice guidelines and protocols available in Croatia | 01/06/06 | 05/06/06 | 01/08/06 | | 01/08/06 |
| 3.3 | Testing guidelines with AGREE instrument, workshop during conference, selection of priority guidelines | 23/09/06 | 23/09/06 | 23/09/06 | | 27/09/06 |
| 3.4 | Workshop on guideline development with working groups | 01/10/06 | | | | 31/10/06 |
| 3.5 | Development of pilot guidelines | 01/11/06 | | | | 31/01/07 |
| 3.6 | Feed back on pilot guidelines from various stakeholders | 01/02/07 | | | | 30/04/07 |
| 3.7 | Formulating of final versions of guidelines | 01/05/07 | | | | 30/09/07 |

| | | | | | | |
|------|---|----------|--|--|--|----------|
| 3.8 | Publication of guidelines and implementation tools | 01/11/07 | | | | 30/11/07 |
| 3.9 | MRSA reduction strategy in collaboration with national nosocomial infection committee | 01/10/06 | | | | 31/10/06 |
| 3.10 | Introduction of MRSA reduction measures and quality control in selected hospital | 01/01/07 | | | | 30/09/07 |
| 3.11 | Evaluation of MRSA reduction strategy | 01/11/07 | | | | 30/11/07 |

2.2 Human Resource Utilisation

2.2.1 Result 1 ICM

| | Home | Croatia |
|---------------------|------|---------|
| Dr. Jaap Koot | | |
| Prof. Martin Rusnak | | |

2.2.2 Result 2 Surveillance

| | Home | Croatia |
|---------------------|------|---------|
| Dr. Jaap Koot | 4 | 4 |
| Prof. Martin Rusnak | 5 | 5 |
| RIVM | | |
| SWAB | 2 | 6 |
| Dr. Plavec | | 21 |
| | 11 | 36 |

2.2.3 Result 3 Guidelines

| | Home | Croatia |
|---------------------|------|---------|
| Dr. Jaap Koot | | |
| Prof. Martin Rusnak | | |

3 Implementation issues

3.1 Specific Issues

3.2 ICM

The creation of the Insectoral Coordination Mechanism (ISKRA) is in process through a ministerial ordinance, which outlines the membership and tasks. Originally it was planned to produce a policy and work plan in parallel. It was decided that it was more logic to nominate members of ISKRA first and use ISKRA to complete the draft policy and work plan.

3.3 Surveillance

The activities now concentrate on the software and hardware for communication between laboratories. This process is a bit slower than planned. The project has to decide to which extent it will fund for automation of labs, which have no computers at the moment.

3.4 Guidelines

In the process of guideline development it is important to involve a broader group of stakeholders in the process, and to compose working groups, which can speak with authority. Therefore working under the auspices of the ISKRA is important. Starting the working groups may therefore have to wait under ISKRA is formalised.

4 Plans for the next reporting period

4.1 Detailed work plan

4.1.1 Result 1 ICM

The ordinance for initiating the ISKRA is nearly ready and will hopefully be signed by the Minister in October.

There is a preliminary draft of the antimicrobial resistance policy and work plan, which will be presented to ISKRA during its first meeting. Hopefully, ISKRA can endorse it and submit it to the MHSW for approval.

4.1.2 Result 2 Surveillance

The interface software between LIS and WHONET will be completed soon. Communication software between callipers and WHONET is under development.

Procurement of hardware for the National Centre for Antimicrobial Resistance has started.

Before the end of the year the system should be up and running. Dr. Rusnak will coordinate the testing of the communication software.

4.1.3 Result 3 Guidelines

During the last quarter of 2006, working groups will be formed under auspices of ISKRA. Hopefully, it is possible to approach potential members in October and to nominate members officially in November. Tentatively it is planned to have a training in guideline development on 17 and 18 November. Thereafter the working groups can start.

It is also planned to institute a kind of guideline secretariat which will support the working groups in literature search and in administration. The experience of SWAB in guideline development will be used as much as possible in the process.

4.2 Human resources allocation

4.2.1 Result 1 ICM

| | Home | Croatia |
|-----------------------|------|---------|
| Dr. Jaap Koot | 5 | 10 |
| Prof. Martin Rusnak | | |
| Prof. V. Krcmery | | |
| Prof. J. van der Meer | | |
| SWAB | | |
| Dr. Davor Plavec | | 6 |

4.2.2 Result 2 Surveillance

| | Home | Croatia |
|---------------------|-------------|-------------|
| Dr. Jaap Koot | See under 1 | See under 1 |
| Prof. Martin Rusnak | 2 | 4 |
| RIVM | | |
| SWAB | | |
| Dr. Davor Plavec | | 6 |
| | | |

4.2.3 Result 3 Guidelines

| | Home | Croatia |
|---------------------|------|---------|
| Dr. Jaap Koot | | |
| Prof. Martin Rusnak | 2 | 6 |
| Dr. Inge Gyssens | 2 | 4 |
| SWAB | 4 | 8 |
| Dr. Maja Vucetic | 2 | 4 |
| Dr. Davor Plavec | | 10 |
| | | |

Annex 1 Logical Framework

| LOGFRAME PLANNING MATRIX FOR PROJECT: Antimicrobial Resistance Surveillance in Human Medicine MAT05/HR/9/2 | | | |
|---|--|---|--|
| Project duration: 1 January 2006 – 31 December 2007 | | | |
| Overall Objective | Objectively Verifiable Indicators | Means of Verification | |
| The project aims to contribute to the accession of Croatia to the European Union. In particular, the project aims to assist Croatia in implementing EU-directives and recommendations in the field of antimicrobial resistance and the sound use of antibiotics. | Implementation of the Council recommendation (2002/77/EC) on the prudent use of antimicrobial agents | Questionnaire from EU document, COM (2005)684 final, SEC (2005)1746, Brussels, 22.12.2005 | |
| Project Purpose | Objectively Verifiable Indicators | Means of Verification | Assumptions and risks |
| Strengthening the Croatian institutional structure engaged in surveillance of antimicrobial resistance and responsible for measures to reduce antimicrobial resistance | Indicators using in international projects, like EARSS and ESAC, data over 2007 compared to data over 2005 | Official annual reports EARSS and ESAC, benchmarking against other European countries | Commitment of government, insurance and professional organisations toward structure, availability of funding |

| Results | Objectively Verifiable Indicators | Means of Verification | Assumptions and risks |
|--|--|---|--|
| 1. an Intersectoral Co-ordination Mechanism (ICM) in the field of antimicrobial resistance established and functional; | Government MHSW ordinance for ICM, with composition, terms of reference and funding mechanism Policy document approved by Cabinet | Legal document (ordinance) issued by MHSW Budget for 2008, compared to 2005 increased Policy document published | MHSW is cooperative in establishing an ICM and other stakeholders are ready to participate in this structure |
| 2. a surveillance system for antimicrobial resistance and use of antibiotics established, based on national policy that is in line with the EU strategy for antimicrobial resistance | National Surveillance System document approved Automated data communication in place, data collection of full year's samples, and data analysis | Documentation of National Surveillance System publication of annual reports | Financing for surveillance system made available during project period. Hospitals and general practices are willing to collaborate |
| 3. Guidelines for sound use of antibiotics in the human sector formulated and implemented. | Series of guidelines developed, piloted and final versions published | Documentation on guidelines on official website Inspection reports by sanitary inspection | Willingness of stakeholders to collaborate in developing guidelines, piloting and publication. Capacity of hospitals to implement MRSA containment measures |

| | | Remarks |
|--|--|---|
| Activities Result 1 | | |
| Intersectoral Co-ordination Mechanism (ICM) in the field of antimicrobial resistance established and functional | | |
| 1.1 | “zero” assess of implementation of EU recommendations on Antimicrobial Resistance Control | Implemented, details to be sorted out |
| 1.2 | Study visit to the Netherlands | Done |
| 1.3 | Proposal for structure and mandate of the ICM | First draft under production |
| 1.4 | Conference on control of antimicrobial resistance, presentation of design structure and discussion | Presentation made, not yet final design; only drafts |
| 1.5 | Presentation of the proposal to the MHSW, legal instruments for backing up the ICM | Not yet |
| 1.6 | Outline document on policy development: topics and set-up of the document | Done |
| 1.7 | Round table discussions with prospective members of the ICM on policy development | Not yet. Wait until members of ISKRA have been identified |
| 1.8 | Draft policy and circulation among relevant stakeholders | Not yet |
| 1.9 | Presentation policy during conference | Draft presented, not final policy document |
| 1.10 | Final version of policy and presentation to MHSW | Not yet |
| 1.11 | Develop budgets for surveillance activities | Not yet |
| 1.12 | Formulate financing proposals to relevant institutions | Not yet |
| 1.13 | Develop growth scenarios based on available funding | Not yet |

| | | |
|--|--|--|
| Activities Result 2 | | |
| Surveillance system for antimicrobial resistance and use of antibiotics established, based on national policy that is in line with the EU strategy for antimicrobial resistance | | |
| 2.1 | Inventory of automation in laboratories, information and communication | Done |
| 2.2 | Study visit to the Netherlands | Done |
| 2.3 | Plan for Improving ICT in Reference centre and labs | First proposal made, to get approval from reference centre and EVD |
| 2.4 | Improving ICT in Reference centre and improving communication | Software under development, hardware under procurement |
| 2.5 | Presentation of ICT strategy during national conference | Not presented |
| 2.6 | Implementing new communication system between labs | Not yet |
| 2.7 | Testing of new communication system labs | Not yet |
| 2.8 | Evaluation of new communication system | Not yet |
| 2.9 | Final report National Surveillance System | Not yet |
| | | |

| Activities Result 3 guidelines for sound use of antibiotics in the human sector formulated and implemented | | |
|---|--|---|
| 3.1 | Study visit to the Netherlands, discuss guideline development with NHG, SWAB | Done |
| 3.2 | Inventory of existing clinical practice guidelines and protocols available in Croatia | Inventory made and presented on 23 September during workshops |
| 3.3 | Testing guidelines with AGREE instrument, workshop during conference, selection of priority guidelines | Done on 23 September |
| 3.4 | Workshop on guideline development with working groups, that will formulate guidelines | Not yet |
| 3.5 | Development of pilot guidelines | Not yet |
| 3.6 | Feed back on pilot guidelines from various stakeholders | Not yet |
| 3.7 | Formulating of final versions of guidelines | Not yet |
| 3.8 | Publication of guidelines and implementation tools | Not yet |
| 3.9 | MRSA reduction strategy in collaboration with national nosocomial infection committee | Not yet |
| 3.10 | Introduction of MRSA reduction measures and quality control in selected hospital | Not yet |
| 3.11 | Evaluation of MRSA reduction strategy | Not yet |

Annex 2 Gantt Chart

| | | Antimicrobial Resistance Surveillance in Human Medicine | | | | | | | | | | | | Matra Project MAT05/HR/9/2 | | | | | | | | | | | |
|--|--|---|---|---|---|---|---|---|---|---|---|---|---|----------------------------|---|---|---|---|---|---|---|---|---|---|---|
| Gantt Chart and consultants contribution | | 2006 | | | | | | | | | | | | 2007 | | | | | | | | | | | |
| | | J | F | M | A | M | J | J | A | S | O | N | D | J | F | M | A | M | J | J | A | S | O | N | D |
| | Inception phase | ■ | ■ | ■ | | | | | | | | | | | | | | | | | | | | | |
| 1 | Intersectoral Co-ordination Mechanism (ICM) in the field of antimicrobial resistance established and functional | | | | | | | | | | | | | | | | | | | | | | | | |
| 1.1 | “zero” assess of implementation of EU recommendations on Antimicrobial Resistance Control | | | | ■ | | | | | | | | | | | | | | | | | | | | |
| 1.2 | Study visit to the Netherlands | | | | | ■ | | | | | | | | | | | | | | | | | | | |
| 1.3 | Proposal for structure and mandate of the ICM | | | | | | ■ | | | | | | | | | | | | | | | | | | |
| 1.4 | Conference on control of antimicrobial resistance, presentation of DRAFT design structure and discussion | | | | | | | | | ■ | | | | | | | | | | | | | | | |
| 1.5 | Presentation of the proposal to the MHSW, legal instruments for backing up the ICM | | | | | | | | | | ■ | | | | | | | | | | | | | | |
| 1.6 | Outline document on policy development: topics and set-up of the document | | | | | ■ | | | | | | | | | | | | | | | | | | | |
| 1.7 | Round table discussions with prospective members of the ICM on policy development | | | | | ■ | | | | | | | | | | | | | | | | | | | |
| 1.8 | Draft policy and circulation among relevant stakeholders | | | | | | | ■ | | | | | | | | | | | | | | | | | |
| 1.9 | Presentation OUTLINE OF policy during conference | | | | | | | | | | ■ | | | | | | | | | | | | | | |
| 1.10 | Final version of policy and presentation to MHSW | | | | | | | | | | | ■ | | | | | | | | | | | | | |
| 1.11 | Develop budgets for surveillance activities | | | | | | | | | | | | | | | | | | | | | | | | |
| 1.12 | Formulate financing proposals to relevant institutions | | | | | | | | | | | | | | | | | | | | | | | | |
| 1.13 | Develop growth scenarios based on available funding | | | | | | | | | | | | | | | | | | | | | | | | |
| | Dr. Jaap Koot | | ■ | ■ | | | ■ | | | ■ | | | | ■ | | | ■ | | | | | | | | |
| | Dr. Martin Rusnak (partly combined with result 3) | | ■ | ■ | | | ■ | | | ■ | ■ | | | ■ | | | ■ | | | | | | | | |
| | Prof. Krcmery (partly combined with result 3) | | | | | | | | | | | | | | | | | | | | | | | | |
| | Prof. Van der Meer (partly combined with result 3) | | | | | | | | | | | | | | | | | | | | | | | | |
| | SWAB | | | | | | ■ | | | ■ | ■ | | | | | | | | | | | | | | |

| Antimicrobial Resistance Surveillance in Human Medicine | | Matra Project MAT05/HR/9/2 | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|----------------------------|---|---|---|---|---|---|---|---|---|---|---|------|---|---|---|---|---|---|---|---|---|---|---|
| Gantt Chart and consultants contributions | | 2006 | | | | | | | | | | | | 2007 | | | | | | | | | | | |
| | | J | F | M | A | M | J | J | A | S | O | N | D | J | F | M | A | M | J | J | A | S | O | N | D |
| Inception phase | | ■ | ■ | ■ | | | | | | | | | | | | | | | | | | | | | |
| 2. | Surveillance system for antimicrobial resistance and use of antibiotics established, based on national policy that is in line with the EU strategy for antimicrobial resistance | | | | | | | | | | | | | | | | | | | | | | | | |
| 2.1 | Inventory of automation in laboratories, information and communication | | | | ■ | | | | | | | | | | | | | | | | | | | | |
| 2.2 | Study visit to the Netherlands | | | | | ■ | | | | | | | | | | | | | | | | | | | |
| 2.3 | Plan for Improving ICT in Reference centre and labs | | | | | | ■ | | | | | | | | | | | | | | | | | | |
| 2.4 | Improving ICT in Reference centre | | | | | | | ■ | ■ | ■ | | | | | | | | | | | | | | | |
| 2.6 | Presentation of ICT strategy during national conference | | | | | | | | ■ | | | | | | | | | | | | | | | | |
| 2.7 | Implementing new communication system between labs | | | | | | | | | | ■ | ■ | ■ | | | | | | | | | | | | |
| 2.8 | Testing of new communication system labs | | | | | | | | | | | | | ■ | ■ | ■ | ■ | ■ | ■ | ■ | ■ | | | | |
| 2.9 | Evaluation of new communication system | | | | | | | | | | | | | | | | | | | | | ■ | | | |
| 2.10 | Final report National Surveillance System | | | | | | | | | | | | | | | | | | | | | | | | ■ |
| Consultants input to result 2 | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Dr. Jaap Koot (combines with other results) | | | | | | ■ | | | ■ | | | | | | | | | | | | | ■ | | |
| | Dr. Martin Rusnak (combines with other results) | | | | | | ■ | | | ■ | ■ | | | | | | | | | | | ■ | | | |
| | RIVM | | | | | | | | | | | | ■ | | | | | | | | | | ■ | | |
| | SWAB | | | | | | | | | | | | | | | | | | | | | | | | ■ |

Conference not the right audience for technical explanation

| Antimicrobial Resistance Surveillance in Human Medicine | | Matra Project MAT05/HR/9/2 | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|----------------------------|---|---|---|---|---|---|---|---|---|---|---|------|---|---|---|---|---|---|---|---|---|---|---|
| Gantt Chart and consultants contribution | | 2006 | | | | | | | | | | | | 2007 | | | | | | | | | | | |
| | | J | F | M | A | M | J | J | A | S | O | N | D | J | F | M | A | M | J | J | A | S | O | N | D |
| | Inception phase | ■ | ■ | ■ | | | | | | | | | | | | | | | | | | | | | |
| 3 | guidelines for sound use of antibiotics in the human sector formulated and implemented | | | | | | | | | | | | | | | | | | | | | | | | |
| 3.1 | Study visit to the Netherlands, discuss guideline development with NHG, SWAB | | | | | ■ | | | | | | | | | | | | | | | | | | | |
| 3.2 | Inventory of existing clinical practice guidelines and protocols available in Croatia | | | | | | ■ | | | | | | | | | | | | | | | | | | |
| 3.3 | Testing guidelines with AGREE instrument, workshop during conference, selection of priority guidelines | | | | | | | | ■ | | | | | | | | | | | | | | | | |
| 3.4 | Workshop on guideline development with working groups, that will formulate guidelines | | | | | | | | | ■ | | | | | | | | | | | | | | | |
| 3.5 | Development of pilot guidelines | | | | | | | | | | ■ | ■ | ■ | | | | | | | | | | | | |
| 3.6 | Feed back on pilot guidelines from various stakeholders | | | | | | | | | | | | | ■ | ■ | ■ | | | | | | | | | |
| 3.7 | Formulating of final versions of guidelines | | | | | | | | | | | | | | | | | | ■ | ■ | ■ | ■ | | | |
| 3.8 | Publication of guidelines and implementation tools | | | | | | | | | | | | | | | | | | | | | | | ■ | |
| 3.9 | MRSA reduction strategy in collaboration with national nosocomial infection committee | | | | | | | | | | ■ | | | | | | | | | | | | | | |
| 3.10 | Introduction of MRSA reduction measures and quality control in selected hospital | | | | | | | | | | | | | ■ | ■ | ■ | ■ | ■ | ■ | ■ | ■ | ■ | ■ | ■ | ■ |
| 3.11 | Evaluation of MRSA reduction strategy | | | | | | | | | | | | | | | | | | | | | | | | ■ |
| | Dr. Jaap Koot | | | | | | ■ | | | ■ | | ■ | | | | | | ■ | | | | | | ■ | |
| | Dr. Maja Vucetic | | | | | | | | | | ■ | | | | | | | | ■ | | | | | | |
| | Dr. Martin Rusnak (partly combined with result 1) | | | | | | ■ | | | ■ | | ■ | | | | | | | | | | | | | |
| | Dr. Health Houlihan | | | | | | | | | | | | | | | | | | | | | | | ■ | |
| | SWAB | | | | | | | | | ■ | | ■ | | | | | | ■ | | | | | | ■ | |
| | Dr. Gyssens | | | | | | | | | | ■ | | | | | | | | ■ | | | | | | |

| | |
|--|--|
| | Programme activity of several weeks/months |
| | Single event planned during project |
| | Implementation according to plan |
| | Postponed (with explanation) |
| | Mission by consultant (mostly 5 days) |

Annex 3 Report workshops 23 September 2006

Workshop evaluation Croatian Clinical Guidelines with the AGREE instrument

1. Therapy and Prevention of Urogenital Infections

- a. No GPs were included, other professions are.
- b. It is not clear if there was patients' involvement. No info on pilot testing.
- c. It is not clear if national evidence was used. No previous external review. No procedure on updating guidelines was explicitly specified.
- d. Recommendations are hard to recognize
- e. Applicability is dubious.
- f. Overall assessment: Recommended (with provisions or alterations)

| Urogenital Infections | | |
|---------------------------|--------------------------|-------|
| Standardized Domain Score | Scope and Purpose | 100.0 |
| | Stakeholder Involvement | 41.7 |
| | Rigour of Development | 66.7 |
| | Clarity and Presentation | 83.3 |
| | Applicability | 77.8 |
| | Editorial Independence | 66.7 |
| | Median Score | 72.2 |

OVERALL ASSESSMENT

| | App 1 | App 2 | App 3 | App 4 |
|----------------------|-------|-------|-------|-------|
| Strongly Recommended | | | | |
| Recommended | X | | | |
| Would not Recommend | | | | |
| Unsure | | | | |

2. Acute Bacterial Sinusitis

- a. None
- b. Stakeholder involvement was low,
- c. Methodology poor,
- d. None
- e. None
- f. Independence was not declared.
- g. NOT RECOMMENDED (The purpose of the guidelines was missed)

| Acute Bacterial Sinusitis | | |
|---------------------------|--------------------------|------|
| Standardized Domain Score | Scope and Purpose | 88.9 |
| | Stakeholder Involvement | 8.3 |
| | Rigour of Development | 17.5 |
| | Clarity and Presentation | 17.5 |
| | Applicability | 0.0 |

| | |
|------------------------|------|
| Editorial Independence | 0.0 |
| Median Score | 12.9 |

OVERALL ASSESSMENT

| | App 1 | App 2 | App 3 | App 4 |
|----------------------|-------|-------|-------|-------|
| Strongly Recommended | | | | |
| Recommended | | | | |
| Would not Recommend | X | X | X | |
| Unsure | | | | |

3. SORE THROAT 2-PLIVA

- a. Objectives are only partly described. Clinical questions are not touched.
- b. Stakeholders involvement was minimal; Patients preferences were not taken into account. No info on piloting.
- c. Methodology is not described.
- d. Clarity-unclear, no tools for application.
- e. Applicability questionable.
- f. Independence-dubious since it was published by PLIVA
- g. Summary: NOT RECOMMENDED

| SORETHROAT 2-PLIVA | | |
|---------------------------|--------------------------|------|
| Standardized Domain Score | Scope and Purpose | 47.2 |
| | Stakeholder Involvement | 10.4 |
| | Rigour of Development | 27.4 |
| | Clarity and Presentation | 16.7 |
| | Applicability | 11.1 |
| | Editorial Independence | 0.0 |
| | Median Score | 13.9 |

OVERALL ASSESSMENT

| | App 1 | App 2 | App 3 | App 4 |
|----------------------|-------|-------|-------|-------|
| Strongly Recommended | | | | |
| Recommended | | | | |
| Would not Recommend | X | X | X | X |
| Unsure | | | | |

4. Otitis Media

- a. all is OK
- b. Stakeholders-GPs were not included. Target users were not defined. Piloted, not clear
- c. Sources of literature were mentioned, but no systematic approach no updating,
- d. Not adequately defined, but most questions answered
- e. No organizational / costs mentioned
- f. Conflicts of interest were not mentioned.
- g. Summary: RECOMMENDED BUT WILL HAVE TO BE IMPROVED

| Otitis Media | | |
|---------------------------|--------------------------|------|
| Standardized Domain Score | Scope and Purpose | 88.9 |
| | Stakeholder Involvement | 0.0 |
| | Rigour of Development | 9.5 |
| | Clarity and Presentation | 58.3 |
| | Applicability | 0.0 |
| | Editorial Independence | 0.0 |
| | Median Score | 4.8 |

OVERALL ASSESSMENT

| | App 1 | App 2 | App 3 | App 4 |
|----------------------|-------|-------|-------|-------|
| Strongly Recommended | | | | |
| Recommended | X | X | X | X |
| Would not Recommend | | | | |
| Unsure | | | | |

5. Surgical Treatment of Tonsillar Disease

- a. Definition of the disease was not well stated.
- b. No GPs and pediatricians involved.
- c. Literature is too old, not graded.
- d. Clarity is unacceptable. Target audience is not clear.
- e. Applicability is zero
- f. NOT RECOMMENDED

| Surgical Treatment of Tonsillar Disease | | |
|---|--------------------------|------|
| Standardized Domain Score | Scope and Purpose | 22.2 |
| | Stakeholder Involvement | 0.0 |
| | Rigour of Development | 1.6 |
| | Clarity and Presentation | 22.2 |
| | Applicability | -7.4 |
| | Editorial Independence | 88.9 |
| | Median Score | 11.9 |

OVERALL ASSESSMENT

| | App 1 | App 2 | App 3 | App 4 |
|----------------------|-------|-------|-------|-------|
| Strongly Recommended | | | | |
| Recommended | | | | |
| Would not Recommend | X | X | X | |
| Unsure | | | | |

6. Sore Throat II

7.

- a. This is not guidelines-only one study was used. It was a proposal from the year 2000.
- b. Objectives are not defined, Stakeholders not included.
- c. Aims are not defined. References missing.
- d. Recommendations are too general.
- e. No studies were performed.

- f. Interests were not declared.
- g. Summary: Not recommended.

| Sore Throat II | | |
|---------------------------|--------------------------|------|
| Standardized Domain Score | Scope and Purpose | 52.8 |
| | Stakeholder Involvement | 22.9 |
| | Rigour of Development | 19.0 |
| | Clarity and Presentation | 52.1 |
| | Applicability | 33.3 |
| | Editorial Independence | 50.0 |
| | Median Score | 41.7 |

OVERALL ASSESSMENT

| | App 1 | App 2 | App 3 | App 4 |
|----------------------|-------|-------|-------|-------|
| Strongly Recommended | | | | |
| Recommended | | | | |
| Would not Recommend | X | X | X | X |
| Unsure | | | | |

8. Acute Resp. Infections-PLIVA

- a. One person wrote it. No stakeholders.
- b. No methodology applied or described.
- c. Clarity no specific ATB mentioned.
- d. Key recommendations described. No org. barriers described.
- e. Info on independence missing.
- f. Summary: Not recommended (good for education)
- g. General: It was difficult to evaluate.

| Acute Resp. Infections | | |
|---------------------------|--------------------------|------|
| Standardized Domain Score | Scope and Purpose | 33.3 |
| | Stakeholder Involvement | 8.3 |
| | Rigour of Development | 4.8 |
| | Clarity and Presentation | 33.3 |
| | Applicability | 22.2 |
| | Editorial Independence | 0.0 |
| | Median Score | 15.3 |

OVERALL ASSESSMENT

| | App 1 | App 2 | App 3 | App 4 |
|----------------------|-------|-------|-------|-------|
| Strongly Recommended | | | | |
| Recommended | X | X | | |
| Would not Recommend | | | | |
| Unsure | | | | |

9. Summary of scores for all guidelines

| | Guideline | GUIDELINE | | | | | | | Median Score |
|---------------------------|--------------------------|-----------------------|---------------------------|---------------------|--------------------|---|----------------|---|--------------|
| | | Urogenital Infections | Acute Bacterial Sinusitis | Sore Throat (PLIVA) | Acute Otitis Media | Surgical Treatment of Tonsillar Disease | Sore Throat II | Acute Respiratory Infections for Outpatient Treatment | |
| Standardized Domain Score | Scope and Purpose | 100,0 | 88,9 | 47,2 | 88,9 | 22,2 | 52,8 | 33,3 | 52,8 |
| | Stakeholder Involvement | 41,7 | 8,3 | 10,4 | 0,0 | 0,0 | 22,9 | 8,3 | 8,3 |
| | Rigour of Development | 66,7 | 17,5 | 27,4 | 9,5 | 1,6 | 19,0 | 4,8 | 17,5 |
| | Clarity and Presentation | 83,3 | 17,5 | 16,7 | 58,3 | 22,2 | 52,1 | 33,3 | 33,3 |
| | Applicability | 77,8 | 0,0 | 11,1 | 0,0 | -7,4 | 33,3 | 22,2 | 11,1 |
| | Editorial Independence | 66,7 | 0,0 | 0,0 | -16,7 | 88,9 | 50,0 | 0,0 | 0,0 |
| | Median Score | 72,2 | 12,9 | 13,9 | 4,8 | 11,9 | 41,7 | 15,3 | 13,9 |

10. Discussion

New guidelines in Croatia should adhere to AGREE principles. All guidelines have been developed by small groups so far. There has not been sufficient input from relevant stakeholders.

According to Dr. Prins there should be more emphasis on the rigorous methodology application. The question is how to motivate busy practitioners to contribute to the guideline development. The MoH motivated people to produce guidelines in the year 2000, in the context of a quality assurance project, but the process was not finished.

Dr. Tambic summarises the conclusions: Croatia needs guidelines, and they should become recognized. Presently, there is a lack of motivation to get involved. Stakeholders involvement has to be explicitly addressed by ISKRA. Who should be involved? Suggestion is to involve clinical microbiologists, pharmacologists, GPs, intensivists and the patients and consumers association. Medical societies will be requested to appoint people in working groups for guideline development. Funding of the activity should be requested from the MHSW. There is a need for a facilitator in collection of information, possibly a librarian..

Guidelines to start with in the working groups:

Tonsillopharyngitis, Urinary Tract Infections, Surgical Prophylaxis, Otitis media, MRSA (without treatment)

Workshop on MRSA

Introductions were given by Dr. Vos (the Netherlands), Prof. Dr. French (UK) and Dr. Payern-Pal (Croatia)

After discussion the consensus was reached to select several pilot hospitals for MRSA reduction trial, Split, Rieka, Zagreb, Belovar, Zadar & Dubrovnik.

Dr. Tambic summarises conclusions of the MRSA workshop:

There is a need for a timely and systematic local surveillance. More data are needed on actual prevalence of MRSA. condition is an access to IT, screening, National policy should define an outbreak detection. Strengthening the role of Infection Control team, Infectious Disease doctor in particular. Further activities will address auditing, surveillance, better collaboration with clinicians. Education. There is a need for obtaining support of the Hospital management and to strengthen the role of health insurance. National guidelines should be developed.

